Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Targeted Therapy 1Neoplasms 1Myeloproliferative Disorders 1Glioma 1Cholangiocarcinoma 1

Interventions

fludarabine 10ruxolitinib 9fludarabine phosphate 9Whole-Body Irradiation 9Specimen Handling 9Cyclophosphamide 8Azacitidine 8Mycophenolic Acid 7Cytarabine 7Busulfan 7Biopsy 7Tacrolimus 6venetoclax 5Stem Cell Transplantation 5Sirolimus 5Peripheral Blood Stem Cell Transplantation 5Injections 5Granulocyte Colony-Stimulating Factor 5Melphalan 4Cyclosporine 4CPX-351 4luspatercept 3ivosidenib 3decitabine and cedazuridine drug combination 3Thiotepa 3Methotrexate 3Liposomes 3Idarubicin 3Daunorubicin 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × olutasidenib × 90 days × Clear all
NCT05564390 2026-06-03

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡